Long-term therapy with ETV or TDF demonstrates positive 5-year survival in patients with chronic HBV

Data show that the long-term use of entecavir or tenofovir results in excellent five-year survival for Caucasian patients with chronic hepatitis B, with more than 95 percent of patients surviving at five years and a significant proportion of deaths coming from liver-unrelated causes.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1HA05Cf